| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K71781559 | CTRPv2 | pan-cancer | AAC | -0.0073 | 0.9 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.01 | 0.9 |
| mRNA | AZD7762 | GDSC1000 | pan-cancer | AAC | -0.0065 | 0.9 |
| mRNA | Gemcitabine | GDSC1000 | pan-cancer | AAC | 0.0068 | 0.9 |
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | 0.0066 | 0.9 |
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | -0.0077 | 0.9 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.011 | 0.9 |
| mRNA | navitoclax:PLX-4032 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | -0.0065 | 0.9 |